Detalhe da pesquisa
1.
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Mol Cancer Ther
; 21(7): 1047-1059, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511740
2.
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Mol Cancer Ther
; 19(11): 2235-2244, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32967924